Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "deoxyribozymes" wg kryterium: Temat


Wyświetlanie 1-2 z 2
Tytuł:
Regulacja aktywności katalitycznej rybozymów HDV oraz deoksyrybozymów za pomocą antybiotyków i jonów metali
Regulation of the catalytic activity of HDV ribozymes and deoxyribozymes with antibiotics and metal ions
Autorzy:
Wrzesinski, J.
Ciesiołka, J.
Powiązania:
https://bibliotekanauki.pl/articles/171740.pdf
Data publikacji:
2018
Wydawca:
Polskie Towarzystwo Chemiczne
Tematy:
antybiotyki
rybozymy HDV
deoksyrybozymy
jony metali
antibiotics
HDV ribozymes
deoxyribozymes
metal ions
Opis:
This review article describes the results of a 15-year cooperation between the Department of RNA Biochemistry at the Institute of Bioorganic Chemistry, Polish Academy of Sciences in Poznań and the Medical Chemistry Team of the Faculty of Chemistry at the University of Wrocław, headed by Professor Małgorzata Jeżowska- -Bojczuk. A wide spectrum of antibiotics and other low molecular compounds and their complexes with Cu2+ ions have been tested as potential inhibitors of the HDV ribozyme catalytic reaction. Unexpectedly, it has been found that a number of compounds, depending on the conditions, exhibit inhibitory or stimulatory properties, i.e. they act as modulators of the RNA catalysis process. It was found that the effect of stimulation / inhibition of the catalytic activity of the HDV ribozyme is closely related to the degree of protonation of the antibiotics under study in given conditions. Their ability to inhibit catalysis also increases after binding the Cu2+ cation. In an environment with a higher pH, antibiotics usually stimulate the cleavage reaction, as at least some of their nitrogen centers are allowed to participate in the catalysis reaction, as proton acceptors / donors or a catalytic metal ion coordination site. During the study of one of the antibiotics, bacitracin, it was also observed that it exhibits nucleolytic properties with RNA and DNA molecules. The discovery of the hydrolytic properties of bacitracin extended the potential use of this antibiotic in antiviral therapy with the aim to destroy undesired nucleic acids in the cell. To search for DNAzymes catalyzing RNA hydrolysis, the in vitro selection method was used. In the selection experiment aimed at obtaining DNAzymes active in the presence of Cd2+ ions, variants belonging to the family of DNAzymes 8–17 previously described in the literature were obtained. Analysis of their properties showed that not only Cd2+ but also Zn2+ and Mn2+ ions support catalysis, therefore the site of catalytic metal ion coordination is not highly specific. The DNAzymes obtained in the second selection experiment showed an optimum of catalytic activity in the pH range of 4.0–4.5 and were inactive at a pH higher than 5.0. Interestingly, they do not require the presence of any divalent metal ions as cofactors in the catalysis reaction. The obtained results broaden the repertoire of DNAzymes which operate under non-physiological conditions and bring new information on the possible mechanisms of reactions catalyzed by nucleic acids.
Źródło:
Wiadomości Chemiczne; 2018, 72, 7-8; 397-415
0043-5104
2300-0295
Pojawia się w:
Wiadomości Chemiczne
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Targeting BACE with small inhibitory nucleic acids - a future for Alzheimers disease therapy?
Autorzy:
Nawrot, Barbara
Powiązania:
https://bibliotekanauki.pl/articles/1043280.pdf
Data publikacji:
2004
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
β-amyloid peptide
deoxyribozymes
small interfering RNAs
hammerhead ribozymes
Alzheimer's disease
β-secretase
Opis:
β-Secretase, a β-site amyloid precursor protein (APP) cleaving enzyme (BACE), participates in the secretion of β-amyloid peptides (Aβ), the major components of the toxic amyloid plaques found in the brains of patients with Alzheimer's disease (AD). According to the amyloid hypothesis, accumulation of Aβ is the primary influence driving AD pathogenesis. Lowering of Aβ secretion can be achieved by decreasing BACE activity rather than by down-regulation of the APP substrate protein. Therefore, β-secretase is a primary target for anti-amyloid therapeutic drug design. Several approaches have been undertaken to find an effective inhibitor of human β-secretase activity, mostly in the field of peptidomimetic, non-cleavable substrate analogues. This review describes strategies targeting BACE mRNA recognition and its down-regulation based on the antisense action of small inhibitory nucleic acids (siNAs). These include antisense oligonucleotides, catalytic nucleic acids - ribozymes and deoxyribozymes - as well as small interfering RNAs (siRNAs). While antisense oligonucleotides were first used to identify an aspartyl protease with β-secretase activity, all the strategies now demonstrate that siNAs are able to inhibit BACE gene expression in a sequence-specific manner, measured both at the level of its mRNA and at the level of protein. Moreover, knock-down of BACE reduces the intra- and extracellular population of Aβ40 and Aβ42 peptides. An anti-amyloid effect of siNAs is observed in a wide spectrum of cell lines as well as in primary cortical neurons. Thus targeting BACE with small inhibitory nucleic acids may be beneficial for the treatment of Alzheimer's disease and for future drug design.
Źródło:
Acta Biochimica Polonica; 2004, 51, 2; 431-444
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies